Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
PERRIGO ISRAEL PHARMACEUTICALS LTD. et al v. UNITED STATES FOOD AND DRUG ADMINISTRATION
Case Number:
1:14-cv-00475
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
July 24, 2014
FDA Gives Equivalent Rating To Perrigo's Testosterone Gel
The U.S. Food and Drug Administration on Thursday granted Perrigo Co. an AB therapeutic equivalent rating for its testosterone gel, concluding that the generics maker's product is therapeutically equivalent to AbbVie's AndroGel and effectively mooting a suit by Perrigo seeking such a determination.
-
April 22, 2014
Perrigo Wants Hurry-Up On Delayed FDA Drug Rating
Perrigo Co. on Monday urged a Washington, D.C., federal judge to order the U.S. Food and Drug Administration to update its records to reflect its approval of Perrigo's testosterone gel product within 21 days, saying it will be irreparably harmed otherwise.
-
April 14, 2014
FDA Seeks To Stay Perrigo Suit Over Delayed Rating Update
The U.S. Food and Drug Administration on Thursday asked a D.C. federal judge to stay a suit from Perrigo Israel Pharmaceuticals Ltd. alleging the agency has failed to update its records to reflect the "therapeutic equivalence" rating of Perrigo's generic testosterone gel product, blasting the company for asserting "speculative harms" in its complaint.
-
March 24, 2014
Perrigo Sues FDA For Failing To Publish Approval Of Gel
Perrigo Israel Pharmaceuticals Ltd. on Friday sued the U.S. Food and Drug Administration in D.C. federal court, alleging the agency has failed to update its records to reflect its approval of Perrigo's testosterone gel product.